FDA accepts Supplemental BLA for Opdivo + Yervoy for Patients with Unresectable or Metastatic MSI-H or MRD CRC March 4, 2025
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline March 4, 2025
First New Subject Dosed in Ph 2 Study of Ampligen and Imfinzi Combination Therapy for Late-Stage Pancreatic Cancer March 4, 2025
Positive Final Survival Data from Ph 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Announced March 4, 2025
FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer March 4, 2025
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers March 4, 2025
Camizestrant demonstrated highly statistically significant improvement in PFS in 1L advanced HR+ve breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Ph 3 trial March 4, 2025
FDA Grants Priority Review to KEYTRUDA + SOC as Perioperative Treatment for Resectable Locally Advanced SCCHN; PDUFA: Jun 23, 2025 March 4, 2025
Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm’s Innovative T Cell Therapies for Solid Cancers March 4, 2025
Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 March 4, 2025
First Dose Cohort in STARLIGHT-1 Trial Completed and Approval Received to Initiate Higher Dose Cohort March 4, 2025
GEMSTONE-303 article published in JAMA, highlighting efficacy of sugemalimab + CAPOX vs placebo + CAPOX as 1L treatment for patients with unresectable locally advanced/metastatic G/GEJ adenocarcinoma with PD-L1 CPS ≥5 March 4, 2025
Additional Positive Data from Ph 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors Presented March 4, 2025
Positive Clinical Data Demonstrating Survival and Clinical Responses with triple combination of Versamune® HPV, PDS01ADC and a PD-L1 inhibitor in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology March 4, 2025
FDA RMAT Designation for CAR-NK in Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer March 4, 2025
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable NSCLC March 4, 2025
Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy March 4, 2025
